Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy
作者： J.-M. Nabholtz , H. J. Senn , W. R. Bezwoda , D. Melnychuk , L. Deschênes
DOI: 10.1200/JCO.1999.17.5.1413
关键词:
摘要: PURPOSE: This phase III study compared docetaxel with mitomycin plus vinblastine (MV) in patients metastatic breast cancer (MBC) progressing despite previous anthracycline-containing chemotherapy. PATIENTS AND METHODS: Patients (n = 392) were randomized to receive either 100 mg/m2 intravenously (IV) every 3 weeks 203) or 12 IV 6 189), for a maximum of 10 3-week cycles. RESULTS: In an intention-to-treat analysis, produced significantly higher response rates than MV overall (30.0% v 11.6%; P < .0001), as well visceral involvement (30% 11%), liver metastases (33% 7%), resistance anthracycline agents 7%). Median time progression (TTP) and survival longer (19 11 weeks, .001, 11.4 8.7 months, .0097, respectively). Neutropenia grade 3/4 was more frequent (93.1% 62.5%; .05); t...
sci-hub.se 参考文章(21)
J.H. Beijnen, I.A.M. Mandjes, W.W. ten Bokkel Huinink, M.T. Huizing, J.B. Vermorken, H.M. Pinedo, F. Bierhorst, J.J. Heimans, B. Winograd, T.J. Postma, High dose Paclitaxel with Granulocyte Colony-stimulating factor in patients with advanced breast cancer Refractory to Anthracycline Therapy: A European Cancer Centre Trial Seminars in Oncology. ,vol. 22, pp. 16- 22 ,(1995)
A D Seidman, A Tiersten, C Hudis, M Gollub, S Barrett, T J Yao, J Lepore, T Gilewski, V Currie, J Crown, Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. Journal of Clinical Oncology. ,vol. 13, pp. 2575- 2581 ,(1995) , 10.1200/JCO.1995.13.10.2575
S Jones, E Winer, C Vogel, L Laufman, L Hutchins, M O'Rourke, B Lembersky, D Budman, J Bigley, J Hohneker, Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. Journal of Clinical Oncology. ,vol. 13, pp. 2567- 2574 ,(1995) , 10.1200/JCO.1995.13.10.2567
P. H. Konits, J. Aisner, D. A. Van Echo, K. Lichtenfeld, P. H. Wiernik, Mitomycin C and vinblastine chemotherapy for advanced breast cancer Cancer. ,vol. 48, pp. 1295- 1298 ,(1981) , 10.1002/1097-0142(19810915)48:6<1295::AID-CNCR2820480607>3.0.CO;2-H
Pierre Fumoleau, Andrew D Seidman, Maureen E Trudeau, Bernard Chevallier, WW Ten Bokkel Huinink, Docetaxel: a new active agent in the therapy of metastatic breast cancer. Expert Opinion on Investigational Drugs. ,vol. 6, pp. 1853- 1865 ,(1997) , 10.1517/13543784.6.12.1853
D. Osoba, B. Zee, J. Pater, D. Warr, L. Kaizer, J. Latreille, Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer Quality of Life Research. ,vol. 3, pp. 353- 364 ,(1994) , 10.1007/BF00451727
B. Hoogstraten, S. L. George, B. Samal, S. E. Rivkin, J. J. Costanzi, J. D. Bonnet, T. Thigpen, H. Braine, Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study Cancer. ,vol. 38, pp. 13- 20 ,(1976) , 10.1002/1097-0142(197607)38:1<13::AID-CNCR2820380104>3.0.CO;2-5
Matilde Navarro, Joaquín Bellmunt, Carmen Balañá, Ramón Colomer, Laura Jolis, José M. del Campo, Mitomycin-C and Vinblastine in Advanced Breast Cancer Oncology. ,vol. 46, pp. 137- 142 ,(1989) , 10.1159/000226702
J.A. Radford, R.K. Knight, R.D. Rubens, Mitomycin C and vinblastine in the treatment of advanced breast cancer European Journal of Cancer and Clinical Oncology. ,vol. 21, pp. 1475- 1477 ,(1985) , 10.1016/0277-5379(85)90241-X
L. Gianni, E. Munzone, G. Capri, F. Villani, C. Spreafico, E. Tarenzi, F. Fulfaro, A. Caraceni, C. Martini, A. Laffranchi, P. Valagussa, G. Bonadonna, Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. Journal of the National Cancer Institute. ,vol. 87, pp. 1169- 1175 ,(1995) , 10.1093/JNCI/87.15.1169